MetaCap

Aprea Therapeutics (APRE) vs Xenetic Biosciences (XBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xenetic Biosciences is the larger company by market cap ($3.3 million vs $3.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APRE-62.15%XBIO-36.65%
+5%-30%-65%
Oct 7, 20261 yearNov 20, 2026
APRE-62.11%XBIO-34.27%
+3%-31%-65%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APRE versus XBIO key metrics
MetricAPREXBIO
Share price$0.229$1.40
Market cap$3.25M$3.28M
1-day change-53.56%-9.09%
EPS (TTM)$-0.57$-1.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.98M
Revenue growth (YoY)—+19.04%
Net income (latest FY)$-12.60M$-2.68M
Operating margin—-95.23%
Net margin—-90.07%
52-week high$1.49$4.94
52-week low$0.2036$1.25
Distance from 52-week high-84.63%-71.65%
Analyst consensusnone—
Avg. price target upside+1528.82%—
Average volume388.67K73.30K
Shares outstanding14.19M2.34M
Employees82
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aprea Therapeutics

APRE stock →

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Xenetic Biosciences

XBIO stock →

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

APRE vs XBIO FAQ

Which is bigger, Aprea Therapeutics or Xenetic Biosciences?

Xenetic Biosciences (XBIO) is larger, with a market capitalization of $3.28M compared with $3.25M for Aprea Therapeutics (APRE).

Are Aprea Therapeutics and Xenetic Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons